The generation and characterisation of neutralising antibodies against the Theiler’s murine encephalomyelitis virus (TMEV) GDVII capsid reveals the potential binding site of the host cell co-receptor, heparan sulfate: by Upfold, Nicole et al.
Contents lists available at ScienceDirect
Virus Research
journal homepage: www.elsevier.com/locate/virusres
The generation and characterisation of neutralising antibodies against the
Theiler’s murine encephalomyelitis virus (TMEV) GDVII capsid reveals the
potential binding site of the host cell co-receptor, heparan sulfate
Nicole Upfolda, Caroline Rossb, Özlem Tastan Bishopb, Garry A. Lukec, Caroline Knoxa,⁎
a Department of Biochemistry and Microbiology, Rhodes University, Grahamstown 6140, South Africa
b Research Unit in Bioinformatics (RUBi), Department of Biochemistry and Microbiology, Rhodes University, Grahamstown 6140, South Africa
c Centre for Biomolecular Sciences, School of Biology, Biomolecular Sciences Building, University of St Andrews, North Haugh, St Andrews, Scotland KY16 9ST, UK
A R T I C L E I N F O
Keywords:
Theiler's murine encephalomyelitis virus
Neutralising antibodies
Capsid modelling
Surface epitopes
Heparan sulfate
Molecular docking
A B S T R A C T
The early stages of picornavirus capsid assembly and the host factors involved are poorly understood. Since the
localisation of viral proteins in infected cells can provide information on their function, antibodies against
purified Theiler's murine encephalomyelitis virus (TMEV) GDVII capsids were generated by immunisation of
rabbits. The resultant anti-TMEV capsid antibodies recognised a C-terminal region of VP1 but not VP2 or VP3 by
Western analysis. Examination of the sites of TMEV capsid assembly by indirect immunofluorescence and
confocal microscopy showed that at 5 h post infection, capsid signal was diffusely cytoplasmic with strong
perinuclear staining and moved into large punctate structures from 6 to 8 h post infection. A plaque reduction
neutralisation assay showed that the anti-TMEV capsid antibodies but not anti-VP1 antibodies could neutralise
viral infection in vitro. The VP1 C-terminal residues recognised by the anti-TMEV capsid antibodies were mapped
to a loop on the capsid surface near to the putative receptor binding pocket. In silico docking experiments showed
that the known TMEV co-receptor, heparan sulfate, interacts with residues of VP1 in the putative receptor
binding pocket, residues of VP3 in the adjacent pit and residues of the adjoining VP1 C-terminal loop which is
recognised by the anti-TMEV capsid antibodies. These findings suggest that the anti-TMEV capsid antibodies
neutralise virus infection by preventing heparan sulfate from binding to the capsid. The antibodies produced in
this study are an important tool for further investigating virus-host cell interactions essential to picornavirus
assembly.
1. Introduction
The Picornaviridae comprises a heterogeneous group of medically
and economically important viruses, exemplified by the human and
animal pathogens Poliovirus (PV), Enterovirus 71 (EV71), Foot-and-
mouth disease virus (FMDV) and Theiler’s murine encephalomyelitis
virus (TMEV) (Brito et al., 2015; Morales et al., 2016). The picornavirus
genome encodes a unique large polyprotein with three functional do-
mains which undergo autoproteolytic cleavage to yield all the viral
structural and non-structural proteins necessary for a complete in-
fectious cycle (Jiang et al., 2014). The picornavirus capsid is non-en-
veloped and composed of 60 copies of four capsid proteins VP1-4
(Stanway, 1990). Assembly begins after cleavage of the P1 precursor
into the protein subunits VP0, VP1 and VP3, which immediately as-
semble into the protomer. Five protomers then combine to form the
pentameric subunit of which twelve pentamers interact to yield the
provirion. Finally, cleavage of the VP0 precursor to VP2 and VP4 yields
mature infectious virions. (Jiang et al., 2014; Tuthill et al., 2010).
In the mature picornavirus capsid, VP1-3 interact to create the
capsid shell and are surface exposed, while VP4 is arranged at the inner
surface of the virion. VP1-3 are structurally analogous sharing a wedge-
shaped core of eight β-strands. Strand N and C terminal ends are con-
nected by loops that differ in composition and size (Mateu, 1995).
Variation in the loop amino acid sequences is responsible for differences
in capsid surface topology observed between picornavirus species and
serotypes, and also influences receptor binding and antigenicity of the
virion, thereby affecting host range, tissue tropism and persistence
(Rossmann et al., 2000; Tuthill et al., 2010). The capsid is assembled in
a manner that places five VP1 proteins in protruding mesas around the
5-fold axis, and VP2 and VP3 of different protomers in surface pro-
truding heterohexamers on the 3-fold axis (Cathcart et al., 2014). In
enterovirus capsids, a deep depression, known as the canyon runs
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between the mesa and heterohexamer separating surface exposed loops
of VP1 from those of VP2 and VP3, while in picornaviruses such as
FMDV the depression is reduced or completely absent. In cardiovirus
capsids the 5-fold VP1 mesas are star shaped, whose points disrupt the
canyon resulting instead in a series of hydrophobic pits (reviewed by
Tuthill et al., 2010). Although the precise mechanism of picornavirus
capsid assembly is poorly understood, mutational analyses of a small
number of picornaviruses including FMDV and the enteroviruses, have
identified residues in VP1-3 protein interfaces that are important for
capsid function and structure (Ellard et al., 2017; Mateo et al., 2003;
Rincón et al., 2015; Ross et al., 2017).
The main purposes of the capsid are to protect the viral genome
from environmental conditions and to bind to the host cell to deliver
the genome into the cell’s interior. Once inside the host’s body, enteric
viruses attach specifically to a homologous host cell. The initial catch-
hold between virus and host cell is mediated through sites on the viral
capsid binding to attachment factors on the target cell surface.
Picornaviruses exploit a diverse range of host cell receptors for virus
attachment and entry, including immunoglobulin superfamily receptors
used by PV and cardiovirus encephalomyocarditis virus (EMCV) (Greve
et al., 1991; Huber, 1994; Staunton et al., 1989), integrin cell adhesion
molecules utilised by FMDV (Monaghan et al., 2005) and decay accel-
erating factors used by many enteroviruses (Shieh and Bergelson,
2002). Flexibility in receptor and co-receptor usage has been observed
for many species and is often linked to differences in tissue tropism and
pathogenesis, for example minor group human rhinoviruses (HRVs)
utilise low density lipoprotein receptors (LDLR) while major group
HRVs utilise the intercellular adhesion molecule-1 (ICAM-1). Differ-
ences in TMEV virulence and tissue-tropism are linked to differences in
co-receptor specificity. Neurovirulent strains use heparan sulfate (HS)
and persistent strains use α2,3-linked N-acetylneuraminic acid (sialic
acid) (reviewed by Tuthill et al., 2010).
Investigations into capsid antigenicity have also shown that im-
munogenic epitopes on the virus surface can be the target of protective
neutralising antibody (nAb) responses in the host (reviewed by
Dotzauer and Kraemer, 2012). nAbs play an important role in virus
clearance during primary viral infections and in preventing reinfection.
Epitopes have been identified on all surface exposed capsid proteins
(Meloen Briaire et al., 1983; Westerhuis et al., 2015), however VP1 is
the dominant antigenic protein and contains major neutralising epi-
topes (Cameron et al., 2001; Collen et al., 1991; Edlmayr et al., 2011;
Luo et al., 1992; Mateu, 1995; Nitayaphan et al., 1985; Oberste et al.,
1999; Wu et al., 2001). Neutralisation sites have been mapped to the N
and C termini as well as the EF and GH loops of equine Rhinitis Viruses
(ERAV) VP1 (Horsington et al., 2012; Varrasso et al., 2001) and GH
loops of FMDV VP1 (Collen et al., 1991). In TMEV, neutralising epi-
topes have been mapped to the VP1 CD I and II loops as well as the C
termini of the protein (Ohara et al., 1988; Tan and Cardosa, 2007;
Zurbriggen and Fujinami, 1989) in addition to VP2 EF puff A and B
loops (Inoue et al., 1994).
Aspects of picornavirus replication have been well documented
while capsid assembly, particularly the early steps from P1 to protomer
formation, remains the least understood part of the life cycle. Studies
have revealed only the basic steps of capsid oligomerisation, and that
pentamers can assemble into empty capsids in vitro without assistance
from host cell factors and proteins (Li et al., 2012; Rombaut et al.,
1991). Evidence suggests that multiple viral and cellular components,
such as chaperone proteins of the heat shock family, are required for
capsid assembly, particularly the early stages from P1 cleavage to
pentamer formation (Geller et al., 2007; Jiang et al., 2014; Macejak and
Sarnow, 1992). Few studies have examined the localisation of capsid
subunits during infection, and these have largely been restricted to PV
or FMDV.
Theiler’s murine encephalomyelitis virus (TMEV) is a non-envel-
oped virus belonging to the Cardiovirus genus of the Picornaviridae. All
TMEV strains produce enteric and neurological diseases in mice and are
separated into two subgroups based on their neurovirulence (Lipton,
1980). Theiler’s original (TO) subgroup includes the persistent DA and
BeAn strains which cause an acute demyelinating illness, similar to
multiple sclerosis in humans, while the GDVII and FA strains are highly
neurovirulent and induce acute encephalitis (reviewed by Oleszak
et al., 2004). A replication system in BHK-21 cells is available and, in
this system, we used antibodies against the N-terminal 112 amino acids
of VP1 in immunofluorescence experiments to show that the GDVII VP1
protein colocalises with Hsp90 in the cytoplasm and perinuclear region
of infected cells (Ross et al., 2016). To extend these studies, antibodies
targeting the TMEV capsid proteins (as opposed to VP1 alone) are re-
quired, thus rabbits were immunised with purified TMEV GDVII parti-
cles. The resultant antibodies were used to investigate the localisation
of capsid precursors through the course of TMEV infection. Ad-
ditionally, the neutralising ability of the antibodies and recognition of
linear epitopes near the putative receptor binding site, led to the
identification of the potential binding site of the GDVII co-receptor- HS.
2. Materials and methods
2.1. Cells and virus
BHK-21 cells (kindly provided by M. Ryan, University of St
Andrews, UK) were cultured in buffered Dulbecco’s modified Eagle
Medium (DMEM, Lonza Group Ltd, Basel, Switzerland) supplemented
with 5% heat-inactivated foetal calf serum (FCS), 100 U penicillin
ml−1, 10 mg streptomycin ml−1 and 25 μg fungizone ml−1 with 10%
CO2 at 37° C. The TMEV strain GDVII (GenBank accession no: M20562)
was used to infect cells in all experiments. Virus stocks were prepared
and titred as described previously (Murray et al., 2009). Cells were
infected with virus at a multiplicity of infection (M.O.I) of approxi-
mately 3.
2.2. Preparation and purification of TMEV GDVII particles
Cells cultured in four 75 cm2 flasks grown to 80% confluency were
infected with TMEV in serum-free DMEM at a total volume of 2 ml. The
virus was allowed to adsorb for 1 h at room temperature (RT) with
gentle shaking. 5 ml of serum-free DMEM was added and the flasks
were incubated for 24 h at 37° C to allow for the development of cy-
topathic effect (CPE), after which the flasks were frozen at −20° C. To
facilitate cell lysis, TMEV infected cells were freeze-thawed three times
after which 10% Nonidet P40 (NP-40) (Roche, Germany) was added to
a final concentration of 1% and allowed to incubate for 2 h at RT, with
shaking. Cells were centrifuged at 6 000 x g for 20 min using a JA20
rotor (Beckman centrifuge, USA) and 7% polyethylene glycol (PEG MW
6000) (Merck, RSA) and NaCl to a final concentration of 0.38 M were
added to the supernatant to concentrate the virus particles, followed by
overnight incubation at 4° C. The samples were centrifuged at 11
000 x g at 4° C, for 20 min in Beckman centrifuge tubes using a JA20
rotor. The pellet was resuspended in phosphate buffered saline (PBS)
[137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 (pH 7.4)]
and centrifuged on a 30% sucrose cushion at 171 000 x g using a
Beckman 70.1Ti rotor (Beckman centrifuge, USA) for 4 h at 4° C. The
resultant pellet was resuspended in PBS.
A sucrose gradient was prepared in SW41 tubes (Beckman, USA)
with 10% and 40% sucrose, using a gradient master (BioComp,
Canada). The pellet obtained from the sucrose cushion was placed at
the top of the tube and centrifuged at 96 808 x g using a SW41 rotor
(Beckman, USA) for 2 h at 4° C. The resultant virus band was carefully
removed using a 7-gauge syringe needle, washed using PBS and cen-
trifuged at 151 263 x g in a SW41 rotor (Beckman, USA) for 1 h at 4° C,
and resuspended in 250 μl PBS. 10 μl of the purified virus sample was
denatured using 2X loading buffer [100 mM Tris-Cl (pH 6.8), 4% (w/v)
sodium dodecyl sulfate (SDS), 0.2% (w/v) bromophenol blue, 20% (w/
v) glycerol, 200 mM DTT (diothreitol)] and resolved by 12% SDS-
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PAGE, and stained with coomassie. Approximately 1 mg of the purified
virus sample was used by D. Bellstedt (University of Stellenbosch, South
Africa) for the immunisation of rabbits to generate anti-TMEV capsid
antibodies (Bellstedt et al., 1987).
2.3. Transmission electron microscopy (TEM)
Purified virus was prepared for TEM according Lipton and
Friedmann (1980) except that sodium phosphotungstate was replaced
with a 3% solution of uranyl acetate. Grids were viewed using a Carl
Zeiss Libra 120 PLUS transmission electron microscope and ITEM
software was used to capture the images (Carl Zeiss, Germany).
2.4. Preparation of infected cell lysate and western blot
To produce infected cell lysates, 75 cm2 flasks containing BHK-21
cells were infected with TMEV in serum-free DMEM. Following a virus
adsorption period of 1 h, at RT with shaking, virus inoculum was as-
pirated and the cells rinsed twice with PBS before 5 ml DMEM was
added. The cells were incubated at 37 °C, and harvested at various
hours post infection (hpi). Control cells were mock-infected with serum-
free DMEM. Cells were collected following treatment with trypsin and
centrifugation at 1000 x g and were resuspended in PBS. For Western
analysis experiments, total proteins were denatured in 2X SDS loading
buffer and resolved by 12% SDS-PAGE. Proteins were transferred onto
nitrocellulose membrane (Bio-Rad, USA) before probing with the anti-
TMEV capsid antibodies. Detection was performed using the BM
Chemiluminescence Western Blotting Kit (Roche, Mannheim, Germany)
according to the manufacturer’s instructions. Protein bands were vi-
sualised using the ChemiDoc Molecular Imager XRS+ (Bio-Rad, USA),
and image analysis was performed using the Image Lab™ software,
version 5.1.
2.5. Plasmids
Plasmids containing the TMEV VP1 full length protein and VP1
truncations were constructed. The sequence of TMEV VP1 was obtained
by PCR of pGDVIIFL2, a plasmid that carries the full-length cDNA of
TMEV GDVII (Fu et al., 1990), using the KAPA Taq ReadyMix kit (KAPA
Biosystems, South Africa). The forward primer NUVP1F and reverse
primers NUVP1R, NU1-112R, NU1-195R and NU1-221R were used to
generate the plasmids pVP1 (Full length), pVP1Δ113-276, pVP1Δ196-276,
pVP1Δ222-276 (C-terminal truncations) respectively. Primers NU159-
276F and NU159-276R were used to generate pVP1Δ1-158 (N-terminal
truncation) (Table 1). PCR cycles included an initial denaturation step
at 95° C for 1 min, 30 cycles of: denaturation at 95° C for 1 min, an-
nealing at 60° C for 1 min and elongation at 72° C for 1 min, followed by
a final elongation step at 72° C for 7 min. The PCR products were li-
gated into the plasmid vector pQE-80L (Qiagen, Mannheim, Germany)
by restriction with BamHI and SalI (ThermoFischer Scientific, USA). To
confirm the presence of the inserts and correct open reading frames, all
plasmids were sequenced by Inqaba Biotechnical Industries (Pty) Ltd.,
Pretoria South Africa.
2.6. Protein expression, and analysis
E. coli JM109 cells transformed with pQE-80L, pVP1, pVP1Δ113-276,
pVP1Δ196-276, pVP1Δ222-276 and pVP1Δ1-158 were cultured in Luria
broth (LB) supplemented with 100 μg/ml ampicillin overnight at 37 °C.
Cultures were induced with 1 mM Isopropyl β-D-1-thiogalactopyrano-
side (IPTG) for 4 h and duplicate samples collected each hour.
Centrifugation at 11,800 x g was used to pellet the cells which were
resuspended to equivalent density in PBS. Proteins were denatured
using 2X loading buffer and resolved by 12% SDS-PAGE before being
transferred onto nitrocellulose membrane for Western blotting using
Anti-His6(2) antibodies (Roche, Germany), recognising the 6X histidine
tag in pQE-80L, at a dilution of 1:3000. Anti-TMEV capsid antibodies
were used at a dilution of 1: 20 000.
2.7. Indirect immunofluorescence and confocal microscopy
BHK-21 cells grown on sterile 13 mm glass coverslips in six-well
plates were washed twice with serum-free DMEM before 1:1 TMEV
GDVII virus stock: serum-free DMEM (2 ml total volume) was added to
each well. Following a virus adsorption period of 1 h, at RT with
shaking, virus inoculum was aspirated and the cells rinsed twice with
PBS before 5 ml DMEM was added. The cells were incubated at 37 °C,
and fixed at various hpi. Control cells were mock-infected with serum-
free DMEM. Cells were washed with PBS before fixation with 4% par-
aformaldehyde for 20 min at RT, then rinsed twice with PBS. For
staining, cells were permeabilised in PB (10% sucrose, 0.1% Triton X-
100 in PBS) for 20 min, blocked in PB containing 2% BSA (Block) for
40 min at RT and incubated with antibodies against TMEV GDVII 2C
(1:1000) (Jauka et al., 2010), anti-TMEV VP1 antibodies (1: 20 000)
(Ross et al., 2016) or anti-TMEV capsid antibodies (1:20 000), diluted
in block buffer for 1 h with shaking. Cells were washed twice in PBS
containing 0.1% Tween-20 and incubated with species-specific Alexa
Fluor 546 or 488-conjugated secondary antibodies (Invitrogen, USA)
(1:500) for 30 min. Cells were washed three times, and 4′,6-diamino-2-
phenylindole dihydrochloride (DAPI, Sigma, St Louis, USA) was added
at a final concentration of 0.8 μg/ml in the second wash step to stain the
nucleus. The slides were mounted using Dakofluorescence mounting
medium (Dako Inc., CA, USA) and stored at RT. The helium/neon and
argon lasers at wavelengths 405, 488 and 543 nm were used to excite,
DAPI, Alexa Fluor 488 and Alexa Fluor 546 respectively. Images were
captured using the Zeiss LSM 510-Meta laser scanning confocal mi-
croscope and analysed using Zen software (2012 blue edition, Zeiss,
Germany). To acquire a representative image for each experiment, over
50 cells were viewed at 63 x magnification. Immunofluorescence ex-
periments were performed in triplicate.
2.8. Antibody neutralisation assay
The abilities of anti-TMEV capsid and anti-TMEV VP1 (Ross et al.,
2016) antibodies to neutralise virus infection in vitro were assessed by
measuring the inhibition of viral plaque formation using a plaque re-
duction neutralisation assay. Antibodies were diluted to 1:50, 1:100,
1:500 and 1:1000 in serum-free DMEM. TMEV stocks were diluted in
serum-free DMEM to 10−4. Equal volumes of virus and serum dilutions
were added, giving a final virus dilution of 5 × 10−5 and serum dilu-
tions of 1:100, 1:200, 1:1000 and 1:2000 (in a total volume of 300 μl),
and were left to co-incubate with gentle agitation for 1.5 h at 37° C.
Virus-serum mixtures were then added to confluent BHK-21 monolayers
in 6 well plates, to adsorb for 30 min at RT with gentle agitation and
then 2.5 h at 37° C. The cells were washed with PBS, overlayed with
3 ml of overlay solution (50% DMEM, 1.25% methocel, 60 mM NaCl)
and incubated at 37° C until visible plaques were observed. Cells were
washed and fixed in 4% paraformaldehyde for 15 min at RT then
stained with Coomassie Brilliant Blue. The number of plaques for each
well was counted. Pre-immune serum (final dilution of 1:100) and
Table 1
Primers used to generate plasmids expressing VP1 truncates.
Primer Primer sequence
NUVP1F 5′ AAA GGA TCC GGA ATT GAC AAT GCT G 3′
NUVP1R 5′ AAA GTC GAC TCA CTC AAG CTC AAG AAT G 3′
NU1-112R 5′ AAA GTC GAC TCA CTG TTT GGT CAT GAT GG 3′
NU1-195R 5′ AAA GTC GAC TCA CAG AGG GGA ATT GTA AGG 3′
NU1-221R 5′ AAA GTC GAC TCA ATC CGA CGT AGG AGC AAC 3′
NU159-276F 5′ AAA GGA TCC GTC ACT GAC CAG CTG ATC 3′
NU159-276R 5′ AAA GTC GAC TCA CTC AAG CTC AAG AAT G 3′
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mock-infected controls were used. All experiments were performed in
triplicate.
2.9. In silico virus structure assembly
A homology model of the TMEV GDVII protomer was obtained from
a previous study (Ross et al., 2016). The model did not contain water
molecules or bound ligands. The protomer complex was solvated and
minimised using GROMACS 5.1.2 (Abraham et al., 2015). The complex
was subjected to 1700 steps of steepest descent energy minimisation. A
complete viral capsid was then assembled by superimposing 60 copies
of the minimised protomer on the biological assembly of a template
virus (TMEV DA strain; PDB ID: 1TME) (Grant et al., 1992). It is thought
that the host cell receptor of TMEV is situated in a hydrophobic pit that
is located near the interface between two adjacent protomers around
the five-fold axis. This receptor binding region is the focus of interest
for the docking of the co-receptor HS and can be investigated by locally
analysing any one of the 60 pits within the capsid. Therefore, to lower
the computational cost of the docking studies, a second complex com-
prising of only two adjacent protomers was also assembled. This com-
plex is termed the protomer interface complex.
2.10. Epitope mapping
Two respective epitope regions were mapped to the assembled
TMEV GDVII virus capsid. These regions were VP1 (1–112) and VP1
(222–276). To identify which epitope regions were located on the
surface, the virus capsid was visualised in PyMol (Schrodinger, 2010).
In addition to exploring the location of epitope regions, the suggested
HS binding motif (Reddi and Lipton, 2002) YKKMKV, located in VP1
(240–245), was also mapped to the capsid model.
2.11. Molecular docking
Sialic acid and HS compounds were retrieved from the ZINC data-
base (Irwin and Shoichet, 2005). The two compounds were individually
docked to the protomer interface complex using AutoDock4.2 (Morris
et al., 2010). AutoDock Tools (ADT) were used to prepare the protomer
interface complex and the ligands. The partial charges of the ligands
were assigned using the Gasteiger-Hückel algorithm. Sialic acid binds to
the capsid in a pit located between VP1 loop II and VP2 Puff B (Tsunoda
et al., 2010). Therefore, for sialic acid the grid box was centred on this
pit and spanned an area of residues around a 15 Å radius. The binding
site of HS is unknown. To identify the potential binding site of HS, four
docking simulations were performed. For each simulation, a grid box
spanning a 35 Å radius was centred on a different region across the
protomer interface complex. All docking simulations were carried using
the Lamarckian Genetic Algorithm (LGA) with the following para-
meters: population size of 300, 100 LGA runs, a maximum of 250,000
energy evaluations and a maximum of 27,000 generations. LigPlot+
(Laskowski and Swindells, 2011) was used to determine the residue
interactions between the protomer interface complex and ligands that
docked with the lowest binding energy.
3. Results
3.1. Sucrose gradient purification of TMEV GDVII infected cells yields pure
intact virus particles
To produce polyclonal antibodies against TMEV GDVII capsids,
BHK-21 cells were infected with TMEV GDVII for 24 h and the virus
particles were purified using a 30% sucrose cushion and 10–40% su-
crose gradient. Transmission electron micrographs (Fig. 1A panels a
and b) showed the presence of numerous virus particles roughly 31 nm
in diameter with icosahedral symmetry. Particles that appeared to be
damaged or empty (yellow arrowheads) were also present in the
sample, but were not abundant (Fig. 1A panel b). SDS-PAGE analysis of
denatured capsid samples resolved bands for three proteins at the ex-
pected sizes of 37 kDa, 34 kDa and 27 kDa for TMEV VP1, VP2 and VP3
respectively (Fig. 1B).
3.2. Anti-TMEV capsid antibodies detect VP1 but not VP2, VP3 or VP4 by
western analysis
To determine whether the anti-TMEV capsid antibodies could detect
viral capsid proteins in infected cell lysates, BHK-21 cells were infected
or mock infected with TMEV for a period of 8 h. Cells were collected at
hourly intervals and total cell lysates were analysed by Western blot. A
single protein band of approximately 37 kDa corresponding to VP1 was
detected from 5 hpi in infected cells, and signal increased in intensity as
time progressed to 8 hpi (Fig. 2A). No bands were detected in mock-
infected cell lysate and pre-immune serum could not detect protein
bands in infected or mock infected cell lysates indicating that the an-
tibodies were recognising viral protein.
3.3. Anti-TMEV capsid antibodies recognise linear epitopes in the C-
terminal region of VP1
To define the region of amino acid residues in VP1 recognised by
anti-TMEV capsid antibodies during Western blot experiments, a dele-
tion analysis was performed on the VP1 protein. The full-length VP1
coding sequence and C- or N-terminally truncated coding sequences
were PCR amplified and cloned into pQE-80L (Fig. 2B). Once trans-
formed, expression was induced for 4 h following the addition of IPTG.
Whole cell lysates were used in Western blot experiments using Anti-
His6(2) antibodies to confirm that the expression of each protein was
successful (data not shown). Anti-TMEV capsid antibodies could detect
full-length VP1 as expected (Fig. 2C). The anti-TMEV capsid antibodies
were not able to recognise the VP1C-terminal truncates VP1Δ113-276,
VP1Δ196-276 or VP1Δ222-276, but were able to detect the N-terminal
truncate VP1Δ1-158, mapping the binding region to 54 amino acids
222–276 in the C-terminus of VP1. The anti-TMEV capsid antibodies
were not able to detect the empty pQE-80L vector, as expected
(Fig. 2C).
3.4. TMEV capsid proteins localise to the cytoplasm of infected cells forming
punctate structures towards the end of infection
To examine the subcellular distribution of TMEV capsid precursors
through the course of infection BHK-21 cells were infected or mock
infected with TMEV, fixed with 4% paraformaldehyde at 4, 5, 6, 7 and 8
hpi, and probed with anti-TMEV capsid antibodies. No capsid signal
was detected in mock infected cells (Fig. 3 panel a) or in TMEV infected
cells stained with secondary antibodies alone (Fig. 3 panel b). To con-
firm that cells were successfully infected with TMEV, cells were stained
with anti-TMEV VP1 specific and anti-TMEV 2C antibodies (Fig. 3 pa-
nels c and d). Signal for VP1 was cytoplasmic with increased signal
intensity in the perinuclear region as expected (Ross et al., 2016), while
2C was apparent in the perinuclear replication complex as previously
reported (Jauka et al., 2010; Murray et al., 2009). Following optimi-
sation of anti-TMEV capsid antibodies, a dilution of 1: 20 000 was
found to accurately detect capsid signal without non-specific staining
(data not shown). No signal was observed for TMEV capsid proteins in
cells at 4 hpi (Fig. 3 panel e), however a bright signal was detected from
5 hpi, and was diffusely cytoplasmic, but dominant in the perinuclear
region of the cell (Fig. 3 panel f). The distribution of TMEV capsid
protein changed dramatically from 6 to 8 hpi where the signal moved
progressively into large punctate structures within the cell cytoplasm
(Fig. 3 panels g-i). TMEV capsid proteins remained absent from the
nucleus at all time-points post infection. The same distributions were
observed in all infected cells at respective timepoints, in three in-
dependent experiments.
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3.5. Anti-TMEV capsid antibodies but not anti-TMEV VP1 antibodies
neutralise TMEV infection
To determine whether the anti-TMEV capsid and previously pro-
duced anti-TMEV VP1 antibodies (Ross et al., 2016) were able to neu-
tralise in vitro viral infection, increasing concentrations of sera were
incubated with TMEV virus at a dilution of 5 × 10−5, before the re-
sidual viral infectivity was measured by plaque assay on BHK-21
monolayers. The results indicate that as concentrations of anti-TMEV
capsid containing serum increase, TME viral plaque formation de-
creases dramatically. Sera produced against the N-terminal region of
TMEV VP1 does not neutralise TME virus infection at any concentration
(Fig. 4, A and B). Anti-capsid serum at a dilution of 1: 2000 inhibited
plaque formation ∼5-fold, and up to ∼120-fold at a dilution of 1:100
(Fig. 4B).
3.6. C-terminal residues 254–274 reside on a surface exposed loop
The epitope regions detected by the anti-TMEV capsid and anti-
TMEV VP1 antibodies were mapped to the TMEV GDVII capsid. It is
clear that the anti-TMEV VP1 antibodies previously generated against a
peptide spanning the region VP1 (1–112) recognise regions within the
N-terminal (1–112) amino acids of the protein. Epitopes recognised by
polyclonal antibodies generated against a mature virus particle how-
ever, may be situated anywhere on the capsid surface. The deletion
analysis revealed that the anti-TMEV capsid antibodies bind linear
epitopes located within the region VP1 (222–276). It is likely that the
two sets of antibodies recognise areas in (1–112) and (222–276) that
are exposed on the virus surface, therefore we explored the structural
locations of VP1 (1–112) and VP1 (222–276). The structural mapping
of the TMEV GDVII capsid is shown in Fig. 5. Within the VP1 (1–112)
peptide, three regions are exposed on the surface (47–57), (79–87) and
(95–112). The regions are adjacent to each other and form a larger area
that extends towards the interface between the VP1, VP2 and VP3
subunits (Fig. 5B). The (95–112) region contains VP1 loop II (98–105).
This loop is clearly indicated in the cartoon depiction (Fig. 5C) and
neighbours the VP2 Puff B loop. With regard to VP1 (222–276), the
residues 254–274 are located on the surface of the capsid. These
residues form a loop in the C-terminus of VP1 at the VP1-VP3 interface
(Fig. 5A-C).
3.7. The TMEV host cell co-receptor, heparan sulfate, is predicted to bind to
a pit at the VP1-VP3 interface below the VP1 C-terminal loop
Two co-receptors, sialic acid and HS, were docked to a complex
comprising of two adjacent protomers from the GDVII capsid model.
The binding site of sialic acid has been previously identified as a pit
located between VP1 loop II and VP2 Puff B (Zhou et al., 2000). In this
study, a targeted docking of sialic acid was performed as a control for
docking experiments. The pit between VP1 loop II and VP2 Puff B
marked the centre of a grid box that spanned a 15 Å radius. The docking
results were consistent with previous studies and indicated that sialic
acid has a high binding affinity to this pit. From a total of 100 LGA runs
(Supplementary Table S1), the best docked conformation had a binding
energy of −5.88. The results of the LigPlot analysis (Fig. 6A panel a)
indicate the predicted residue interactions between the docked sialic
acid compound and the viral capsid. As predicted sialic acid binds to
residues of VP1 loop II through electrostatic interactions with R97, S98,
G99, G100 and A104. This loop forms part of the surface exposed region
recognised by the antibodies generated against the peptide VP1
(1–112).
The binding site for HS is unknown, but VP1 (240-YKKMKV-245) is
thought to be a possible HS binding motif (Reddi and Lipton, 2002). To
explore this further the motif was mapped to the viral capsid. The motif
is in fact buried deep within the viral capsid and is not surface exposed,
as such it is unlikely to be the binding site of HS (Fig. 6B). To explore all
possible binding sites across the protomer, a series of four docking si-
mulations were performed, such that in each simulation the grid box
was centred on a different region of the protomer complex. In addition,
a larger grid box spanning a 35 Å radius was defined for each simula-
tion. Out of the four docking simulations, only one revealed high affi-
nity binding for HS to the viral capsid. Specifically, significant docking
results were only observed when the grid box was centred on the VP1
residue L252, situated in a pit directly below the VP1 C-terminus loop
(254–274) and neighbours the VP1 hydrophobic pocket at the VP1-VP3
interface, the suggested binding site of the host cell receptor. HS docked
Fig. 1. TMEV GDVII virus particles purified from infected BHK-21
cells by sucrose cushion and sucrose gradient purification. (A) TEM of
GDVII virus particles following sucrose cushion (top panel) and su-
crose gradient (bottom panel) purification. Yellow arrows indicate
intact empty capsids. (B) Presence of capsid proteins confirmed by
12% SDS-PAGE analysis, following sucrose gradient purification. Mw
(Molecular weight marker in kDa). (For interpretation of the refer-
ences to colour in this figure legend, the reader is referred to the web
version of this article.)
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directly into this pit with a lowest energy conformation of −8.58
(Supplementary Table S2). The residue interactions between HS and the
capsid subunits (Fig. 6A panel b) depict multiple electrostatic and
covalent bonds with VP1 and VP3 residues. Notably, HS docked around
a central VP1 residue F254 that is located in the C-terminus loop re-
cognised by the anti-TMEV capsid antibodies. The molecule also in-
teracts with the P257 residue in the C-terminus loop and with VP1
P153, A154, D155 residues that form part of the hydrophobic pit in the
adjacent protomer. HS also interacts with VP3 T174, S175, Y176, which
are located within the pocket of the local protomer. Ligands bound to
the capsid surface are depicted in Fig. 6C.
4. Discussion
The main aim of this study was to generate polyclonal antibodies
against the TMEV GDVII capsid proteins and characterise their antigen
recognition properties as well as neutralisation ability during TMEV
infection. The antibodies detected the linearised 37 kDa TMEV VP1
protein when purified virus and infected cell lysates were analysed by
Western blotting. It was anticipated that antibodies targeting VP1 epi-
topes would be present in the serum, as VP1 is the most surface exposed
and immunodominant of the capsid proteins (Edlmayr et al., 2011;
Meloen Briaire et al., 1983; Rossmann et al., 1985). Linear epitopes
have also been reported for TMEV VP2 and VP3 (Inoue et al., 1994; Kim
et al., 1992). The inability to detect these linearised epitopes is
therefore unexpected, but is possibly due to low concentrations of
specific antibodies or the presence of conformational epitopes in the
mature capsid. VP4 is the smallest capsid protein at 6 kDa and is ar-
ranged internally in the capsid particle (Jiang et al., 2014; Stanway,
1990), thus the absence of antibodies to linear epitopes in VP4 is not
surprising.
The next experiments investigated the antibody recognition site on
VP1. Linear epitopes have been identified within the VP1 proteins of
many picornaviruses including duck hepatitis A virus (DHAV) (Wu
et al., 2015), enterovirus 71 (EV71) (Zhang et al., 2012) and FMDV
(Yang et al., 2011). In TMEV, epitopes have been identified around
amino acid 101 in DA VP1 (Zurbriggen et al., 1989) and at positions
12–25, 145–160, 262–276 in BeAn VP1 (Inoue et al., 1994). We pre-
viously identified five major surface accessible epitopes in the N-
terminal 1–112 amino acids of VP1 using an in-silico analysis, and
produced responding antibodies against a peptide encoding this N-
terminal region (Ross et al., 2016). We therefore tested whether the
anti-TMEV capsid antibodies would detect epitopes in this highly an-
tigenic region by performing a deletion analysis of the VP1 protein. The
anti-TMEV capsid antibodies could not recognise linear epitopes within
the N-terminal half of VP1, but instead recognised a truncated protein
consisting of C-terminal amino acids 159–276. The in-silico analysis
presented by Ross et al. (2016) also identified epitopes in the C-terminal
amino acids 251–276 of VP1, which are likely those that elicited the
production of the anti-TMEV capsid antibodies.
Fig. 2. Detection of TMEV GDVII VP1 in infected
BHK-21 and bacterial lysates and mapping of linear
antigenic regions in VP1. (A) Western analysis of
TMEV infected BHK-21 lysates at various times post-
infection, using anti-TMEV capsid antibodies. MW
(molecular weight marker in kDa). (B) The strategy
used to generate truncated VP1 his-fusion proteins.
The red boxes represent the his-coding sequence. The
blue boxes represent the truncated regions of VP1.
The numbers above the boxes represent the nucleo-
tide locations. Numbers following Δ denote the de-
leted amino acids. Dashed lines represent the region
recognised by anti-capsid antibodies. (C) Western
Blot of bacterially expressed lysates. Cells were
transformed with plasmid constructs and induced for
4 h using IPTG. Whole cell lysates were analysed by
Western blot using anti-TMEV capsid antibodies to
determine the regions of VP1 detected by the anti-
bodies. MW (molecular weight marker in kDa). (For
interpretation of the references to colour in this
figure legend, the reader is referred to the web ver-
sion of this article.)
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To investigate the localisation of capsid precursors through a time-
course of infection, TMEV infected BHK-21 cells were fixed using 4%
paraformaldehyde from 4 to 8 hpi and probed with anti-TMEV capsid
antibodies. A clear signal was detected from 5 hpi in infected cells but
not in mock infected cells, indicating that the antibodies were specific
for capsid proteins. At 5 hpi the anti-TMEV capsid signal was diffusely
cytoplasmic, with increased signal in the perinuclear region, but was
absent from the nucleus. Similar cytoplasmic localisation patterns have
been observed for the VP1 proteins of FMDV (Knox et al., 2005), PV
(Wychowski et al., 1985) and TMEV GDVII (Ross et al., 2016) and DA
(Nedellec et al., 1998), as well as the VP0, VP1 and VP3 proteins of
EV71 (Liu et al., 2013).
Interestingly, from 6 hpi, the capsid signal changed from a diffuse
cytoplasmic pattern into distinct punctate structures which were most
prominent at 8 hpi and resembled those observed by Nedellec and
colleagues (1998) for TMEV GDVII at 5 hpi. These punctate structures
are possibly intracytoplasmic crystalline arrays formed by the accu-
mulation of viral capsids prior to host cell death, first observed by
Friedmann and Lipton, (1980). Whether these structures are sites of
capsid assembly and membrane associated is yet to be determined al-
though our preliminary data suggests that they do not colocalise with
membranes of the distal secretory pathway (not shown).
Previous studies investigating localisation of viral capsids have in-
volved the use of antibodies targeting the individual capsid proteins as
opposed to antibodies generated against whole capsid (Liu et al., 2013;
Knox et al., 2005; Nedellec et al., 1998; Ross et al., 2016). Whether the
anti-TMEV capsid antibodies in this study recognise individual capsid
proteins, a subset thereof, or epitopes on assembled capsid precursors
isnot known. Although evidence suggests that the individual capsid
proteins are never separate in the cell but rather assemble immediately
into the protomer following cleavage of P1 (Bruneau et al., 1983), the
anti-TMEV antibodies were able to detect VP1 and VP3 but not VP2
when expressed as GFP tagged proteins by immunofluorescence (data
not shown). These results suggest that the antibodies possibly recognise
conformational epitopes on these proteins that are present in the ma-
ture capsid. Additionally, it is unlikely that the anti-capsid antibodies
recognised the immature VP0 precursor, as it is proteolytically cleaved
to the VP2 and VP4 proteins in the mature capsid.
Protective nAbs targeting the surface exposed capsid proteins have
been identified for many picornavirus species including the VP1 and
VP2 proteins of TMEV (Cameron et al., 2001; Inoue et al., 1994; Kim
et al., 1992). Since the anti-TMEV capsid antibodies in this study and
anti-TMEV VP1 antibodies (Ross et al., 2016) recognised linear epitopes
within in the C-terminal and N-terminal regions of VP1 respectively, the
next experiments examined the in vitro neutralising abilities of the two
sets of antibodies. Plaque reduction neutralisation assays demonstrated
that the anti-TMEV VP1 antibodies could not neutralise viral infection,
whereas anti-TMEV capsid antibodies were able to reduce the number
Fig. 3. Subcellular distribution of TMEV capsid proteins in infected BHK-21 cells. Cells were mock infected (panel a), or infected with TMEV (panels b-i), fixed with 4% paraformaldehyde
at 4–8 hpi and stained with anti-TMEV VP1 (5 hpi) (panel c), anti-TMEV 2C (4hpi) (panel d) or anti-TMEV capsid antibodies (4–8 hpi) (panels e-i). Primary antibodies were detected using
species specific Alexa Fluor 488-conjugated or 546-conjugated secondary antibodies. Cells in panel b were probed with secondary 488-conjugated antibodies only. Scale bars = 20 μm.
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of plaques by ∼120-fold when diluted 1:100. Investigations into the
antigenicity of TMEV VP1 have identified nAbs targeting only the C-
terminal region of the protein and not the N-terminus. For example,
Inoue et al. (1994) reported three predominant linear epitopes in BeAn
VP1, namely VP1(12–25), VP1(146–160) and VP1(262–276) with only
VP1(262–276) eliciting nAbs. Furthermore, it is possible that the anti-
TMEV capsid antibodies detect the same VP1(262–276) epitope in
GDVII, as amino acid sequences between the two strains are highly
conserved for this region (data not shown).
Epitopes must be surface exposed to be detected on the mature
capsid particle. Many of the VP1 N-terminal residues described in Ross
et al. (2016) were predicted to be surface exposed in the protomer, but
their location in the mature virus particle was not investigated. Since
we observed that C-terminal but not N-terminal VP1 epitopes elicited
neutralising antibodies, amino acids 1–112 and 222–276 were mapped
to the capsid surface to better understand their locations. Amino acid
Fig. 4. in vitro neutralising abilities of polyclonal anti-TMEV capsid
and anti-TMEV VP1 antibodies. (A) A representative result of three
independent experiments for each treatment. (B) Quantitative com-
parison of the neutralising activities of anti-TMEV capsid and anti-
TMEV VP1 antibodies at increasing concentrations of sera. 100%
confluent BHK-21 cells were infected with TMEV pre-incubated with
increasing concentrations of anti-TMEV capsid and anti-TMEV VP1
sera. After removal of virus-serum inoculum, neutralising ability was
analysed by plaque reduction assay. Neutralising ability is expressed
as the decrease in plaque number with increasing serum concentra-
tion. Pre-immune sera were used as controls for each treatment, at a
dilution of 1:100. All experiments were repeated in triplicate. Error
bars show standard deviation of the mean.
Fig. 5. Structural mapping of the TMEV GDVII
capsid. (A) Homology model of a mature TMEV
GDVII capsid. Subunits are coloured as: Green-VP1;
Pink-VP2; Orange-VP3. Surface exposed residues of
VP1 N-terminal (1–112) containing linear epitopes
detected by the anti-TMEV VP1 antibodies (Ross
et al., 2016): Blue-VP1 residues 47–57, 79–87 and
95–112. Surface exposed residues of VP1 C-terminal
(222–276) containing linear epitopes detected by the
anti-TMEV capsid antibodies: Black-VP1 residues
254–274. (B) Local region showing surface of the
virus. (C) Cartoon depiction of the local capsid re-
gion that contains the predicted surface exposed
linear epitopes.
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residues 47–57, 79–87 and 95–112 were found to be situated near the
VP1-VP3 interface, with residues 98–105 forming VP1 loop II next to
VP2 Puff B. Residues 254–274 were found to form a large flexible loop
at the VP1-VP3 interface. The position of residues 254–274 and their
detection by anti-TMEV capsid antibodies is consistent with multiple
studies that demonstrate that the highly variable loops at the virion
surface are the most exposed residues of the capsid, and typically
contain neutralising epitopes (Luo et al., 1992; Mateu, 1995; Rossmann
et al., 1985). Additionally, this loop protrudes over the lateral extension
of a pit believed to be the binding site for the host cell receptor in DA
and BeAn strains (Grant et al., 1992; Luo et al., 1992).
Host cell receptors have been identified for a number of picorna-
viruses (reviewed by Tuthill et al., 2010). Several investigations have
failed to identify the TMEV host cell receptor but suggest that both
persistent and virulent strains of the virus bind to an unknown 37 kDa
glycoprotein (Kilpatrick and Lipton, 1991). Co-receptors are thought to
assist with host cell receptor binding and different molecules have been
identified as co-receptors for the different TMEV subgroups. Persistent
strains use the N-linked glycoprotein sialic acid as a receptor moiety
(Fotiadis et al., 1991; Shah and Lipton, 2002) while highly-neuroviru-
lent strains use HS, a proteoglycan (Reddi and Lipton, 2002). HS typi-
cally recognises and binds to heparin-binding domains (HBD) which
consist of basic amino acids separated by hydrophobic residues (Cardin
and Weintraub, 1989). A potential HBD in the VP1 C-terminus
(YKKMKV) identified by Reddi and Lipton (2002) was mapped to the
full capsid and is unlikely to be the HS binding site as it is found at
positions 240–245 which are buried deep within the viral capsid. In
silico docking experiments were therefore used to determine the re-
sidues that HS likely binds and these results were used to map HS bound
to the full capsid structure. The results showed that HS interacts with
residues in the hydrophobic pit situated at the VP1-VP3 interface which
is thought to be the host cell receptor binding site (Luo et al., 1992).
Furthermore, HS also interacts with residues in a pocket below and
residues of the C-terminal loop recognised by the neutralising anti-
TMEV capsid antibodies produced in this study. Taken together the
results suggest that the binding of anti-TMEV capsid neutralising
Fig. 6. Residue interactions of TMEV GDVII capsid with sialic acid and heparan sulfate. (A) Residue interactions between the capsid proteins VP1 and VP2 with sialic acid (left panel), and
the capsid proteins VP1 and VP3 with heparan sulfate (right panel). Residues from an adjacent protomer are indicated with italic blue labels. The figures were generated in LigPlot,
subsequent to AutoDock docking simulations. (B) Cross-section through the capsid surface. The motif VP1 240-YKKMKV-245 (predicted by Reddi and Lipton, 2002) is mapped in purple
(circled in black) and lies deep beneath the surface of the capsid. (C) Local region showing docked co-receptors on the surface of the virus. Docked co-receptors are coloured as: Yellow-
sialic acid; Red-heparan sulfate. The hydrophobic pocket is indicated by a half white circle, VP1 C-terminal residues 222–276 are coloured in Black, VP1 residues 47–57, 79–87 and
95–112 are coloured in Blue. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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antibodies to the C-terminal loop hinders HS binding and therefore
receptor binding, preventing viral attachment and entry.
In conclusion, this study generated neutralising anti-TMEV capsid
antibodies that not only detected viral protein in infected cells but also
revealed a potential binding site for the TMEV GDVII co-receptor, HS.
These antibodies provide a valuable tool with which to further in-
vestigate the host cell interactions that govern the capsid assembly
process.
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